HOME ZACKS RESEARCH FUNDS PORTFOLIO BROKER RESEARCH MARKETS SCREENING VIDEO EDUCATION SERVICES
Earnings    EPS Surprises    Mutual Funds    Options            My Account    Help    
Quote:
Login Free Membership
Search:

Top Zacks Features
Free Membership
Premium Home
Zacks Rank
Real Time Insight
Equity Research
My Portfolio
Stock Screener
Premium Screens
ETFs
Mutual Funds
Options
RSS Feed
Profit from the Pros
Subscription Services
Product Guide
Zacks Premium
Method for Trading
Chart Patterns Trader
Home Run Investor
Insider Trader
Options Trader
Reitmeister Trader
Reitmeister Value
Tactical Trader
Top 10 Stocks
Turnaround Trader
Whisper Trader
Research Wizard
Zacks Ultimate



Zacks Premium
Get profitable stock
picks and timely
market advice in
Zacks.com`s Free
Daily Newsletter!

Free Registration

View the Archive

RDY: DR REDDYS LABS LTD - Stock Quote Enter Ticker:
 

QuoteEstimatesCharts Company ReportsNewsFinancials
  Quote |  Detailed Quotes |  Real Time |  Options Chain |  Greeks Montage

DR REDDYS LABS LTD (NYSE)
RDY 32.73 N/A (N/A%) Vol.  0 N/A ET

Zacks Rank: 2 - Buy

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
Zacks Rank Definition Annualized Return
# 1Strong Buy26.83%
# 2Buy18.69%
# 3Hold9.7%
# 4Sell4.03%
# 5Strong Sell1.63%
S&P5009.43%
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank


Day Low - High N/A - N/A
52wk Low - High 28.75 - 39.37
Avg Volume 205,580
Industry MED-GENERIC DRG
Market Cap 5.55 B
Div - Yield 0.23 - 0.72
PE (forward) 17.5
PEG Ratio .7
Current Year Est. 1.87
EPS Last Year 1.70
Detailed Quote


Premium Research: Stock Analysis

Zacks Rank

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
Zacks Rank Definition Annualized Return
# 1Strong Buy26.83%
# 2Buy18.69%
# 3Hold9.7%
# 4Sell4.03%
# 5Strong Sell1.63%
S&P5009.43%
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank


Short-Term Rating 1-3 Months
Zacks #1 Rank Strong Buys Zacks Premium
up 2 - Buy
Zacks Recommendation

Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.

The Zacks Recommendations are split into 3 groups: Outperform, Neutral and Underperform. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock. More on these reports below.

Difference Between Zacks Rank and Zacks Recommendation
Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations


Long-Term Rating 6+ Months
All Outperform Rated Stocks Zacks Premium
PREMIUM
Zacks Industry Rank

Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.

When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

About Zacks Industry Rank
Zacks Industry Rank - All current industry ranks.
Zacks Premium - The only way to get access to the Zacks Industry Rank

PREMIUM
Target Price

The Zacks Price Target provides you our expectation for a stocks share price in the next 6 months. These price targets are created by the Zacks Equity Research group to coincide with their recommendations that are also based on a 6 month time horizon.

Zacks Equity Research Home
Zacks Premium - The only way to get access to the Zacks Price Targets

PREMIUM
Equity Research Report

The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

Zacks Equity Research Home Zacks Premium - The only way to get access to Zacks Recommendations


Updated as of 11/14/2011
PREMIUM
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium

Premium Research: Industry Analysis

Top Peers Ticker Zacks Rank
DR REDDYS LABS LTD RDY 2
AKORN INC AKRX 1
IMPAX LABORATRS IPXL 2
PAR PHARMA COS PRX 2
Top Peer Analysis Zacks Premium
See all MED-GENERIC DRG Peers

BROKERAGE RECOMMENDATIONS
Current ABR 1.00
ABR (Last Week) 1.00
# of Recs in ABR 1
Average Target Price 37.33
Rank in Industry 1 out of 11
More Brokerage Recommendations

Zacks Community PeopleAndPicks.com
Community Rating

PeopleAndPicks.com Community Stock Ratings

Rating Recommendation % of Stocks
5 stars Strong Buy 10%
4 stars Buy 20%
3 stars Hold 40%
2 stars Sell 20%
1 stars Strong Sell 10%
0 stars Not Rated  

We believe that a community of investors working together can create a superior stock rating system. Some call this "collective intelligence". Or simply...together we can beat the market!

A stock's Community Rating is calculated based on the aggregate input of the PeopleAndPicks Community. The proportion of buy to sell ratings, recency of analysis, and the average score of the users who rate it favorably all factor into a score of one to five stars.


How do you rate RDY?
Buy
Sell
Find out what the Zacks Community
thinks of RDY at PeopleAndPicks.com

NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

 Interactive Java Charting
 NEW!   Fundamental Charts




 
ZACKS COMMENTARY FOR RDY
Zacks Blog: The Zacks Analyst Blog Highlights: Dr. Reddy’s Laboratories, Eli Lilly, Johnson & Johnson, Pfizer and AstraZeneca
Feb 07, 2012
Zacks Blog: Dr. Reddy's Going Strong
Feb 06, 2012
Zacks Blog: Medicines Co. Settles with APP
Jan 24, 2012
Zacks Blog: Zacks #5 Rank Additions for Monday
Jan 23, 2012
Zacks Blog: Zacks #5 Rank Additions for Thursday
Jan 19, 2012
Zacks Blog: The Zacks Analyst Blog Highlights: Teva Pharmaceuticals, Mylan, Watson Pharma, Dr. Reddy’s and Novartis
Dec 30, 2011
Zacks Blog: Ring in Generics in 2012 and Beyond
Dec 29, 2011
Zacks Blog: Pfizer's Lipitor in the News
Dec 05, 2011
More Zacks Commentary
NEWS
7 Hot Indian Stocks - Minyanville
Feb 08, 2012
Seven Hot Indian Stocks - Benzinga
Feb 08, 2012
Dr Reddys Laboratories Bearish Moving Average Crossover Alert (RDY)
Feb 07, 2012
Shares of Dr Reddys Laboratories Under Pressure, Down 2.2%
Feb 07, 2012
The Zacks Analyst Blog Highlights: Dr. Reddy's Laboratories, Eli Lilly, Johnson & Johnson, Pfizer and AstraZeneca
Feb 07, 2012
Credit Suisse Downgrades Dr Reddys Laboratories from Outperform to Neutral - Benzinga
Feb 07, 2012
Dr Reddys Laboratories Bearish Moving Average Crossover Alert (RDY) - Story Title - Comtex
Feb 07, 2012
Shares of Dr Reddys Laboratories Under Pressure, Down 2.2% - Story Title - Comtex
Feb 07, 2012
More News
EARNINGS ESTIMATES
  This Quarter
03/2012
Next Quarter
06/2012
This Year
03/2012
Next Year
03/2013
Average Estimate N/A N/A 1.87 1.97
Number of Estimates 0 0 1 1
Low Estimates N/A N/A 1.87 1.97
High Estimate N/A N/A 1.87 1.97
Year Ago EPS 0.37 0.33 1.46 1.87
EPS Growth N/A% N/A% 28.08% 5.35%

More Estimates

COMPANY DESCRIPTION
Doctor Reddy's is an emerging global pharmaceutical company with proven research capabilities. They are vertically integrated with a presence across the pharmaceutical value chain. They produce finished dosage forms, active pharmaceutical ingredients and biotechnology products and market them globally, with focus on India, US, Europe and Russia. They conduct research in the areas of cancer, diabetes, cardiovascular, inflammation and bacterial infection

Full Company Report
FINANCIALS
EPS TTM 1.7
Sales 1677
Net Income 294
Price/Earnings 19.25
Price/Book 5.66
Price/Cash Flow 16.5
Price/Sales 2.95


More Financials

 
About Zacks | Advertise | Affiliate | Media | Careers | Contact Us | Help
Disclaimer | Privacy Policy | Sitemap
NYSE and AMEX data is at least 20 minutes delayed.  NASDAQ data is at least 15 minutes delayed.
Copyright 2012 Zacks Investment Research